India PE/VC investments hit $13.1 bn in Q1 2026, volumes hold steady
Synopsis
India's PE/VC market pulled back on value in Q1 2026 — but the volume story tells a different tale. With 360 deals nearly matching last year's pace and buyouts leading at $4.3 billion, the structural appetite is intact. The real drag is external: geopolitical tension, high crude, and a weakening rupee are keeping foreign capital cautious even as domestic investors hold the line.
Key Takeaways
India PE/VC investments totalled $13.1 billion in Q1 2026 , down 19% year-on-year and 24% quarter-on-quarter .
Deal volumes were nearly flat at 360 transactions , versus 366 in Q1 2025 and 358 in Q4 2025.
27 large deals accounted for $8.7 billion — about two-thirds of total investment.
Buyouts led by deal type at $4.3 billion ; technology led by sector at $2.2 billion .
Pharma and medical devices have attracted $16.4 billion across 303 deals since 2016, with 62% in the last five years.
Geopolitical tensions, high crude prices, and rupee depreciation cited as key headwinds by EY's Vivek Soni .
India's private equity and venture capital (PE/VC) investment activity moderated in Q1 2026, with total deal value easing to $13.1 billion — down 19% year-on-year and 24% quarter-on-quarter — even as deal volumes remained largely flat, according to a joint report by EY and the Indian Venture Capital Association (IVCA) released on 30 April 2026. The findings point to a market navigating geopolitical headwinds while retaining structural depth.
Deal Value and Volume Trends
A total of 360 transactions were recorded in Q1 2026, virtually unchanged from 366 deals in the same period a year earlier. Compared to Q4 2025, deal volumes edged up 1% from 358 transactions, signalling that investor appetite for deal-making remains intact even as headline value figures retreated from recent peaks.
Large deals continued to drive value concentration. 27 large transactions alone accounted for $8.7 billion — roughly two-thirds of total Q1 2026 PE/VC investment — underscoring a market where a handful of big-ticket bets determine the aggregate picture.
Where Capital Flowed
By deal type, buyouts led with $4.3 billion, followed by growth investments at $4.1 billion and start-up funding at $3.2 billion. Sector-wise, technology attracted the most capital at $2.2 billion, followed by financial services at $2 billion and real estate at $1.9 billion. Together, these three sectors accounted for 47% of overall investments in the quarter.
Real estate and infrastructure as an asset class moderated by 11% to $3.4 billion in Q1 2026, down from $3.9 billion in Q1 2025. Quarter-on-quarter, the decline was sharper — real estate and infrastructure investments fell 51% from $6.9 billion in Q4 2025, while pure-play PE/VC investments dropped a comparatively modest 7% from $10.4 billion.
Pharma and MedTech: A Decade of Rising Interest
The pharmaceutical and medical devices sector has emerged as a long-term favourite. Since 2016, the sector has attracted $16.4 billion across 303 deals, with 62% of that investment recorded in just the last five years — a trajectory the EY-IVCA report describes as consistently upward over the past decade.
What Is Weighing on Sentiment
Vivek Soni, Partner and National Leader, Private Equity Services at EY, attributed the moderation to a confluence of external pressures.
Point of View
But volume resilience suggests deal pipelines are not drying up — investors are simply being more selective and cautious on sizing. The rupee's sustained slide is the underappreciated variable here: it erodes dollar-denominated returns for foreign LPs even when Indian fundamentals hold. Until currency volatility stabilises, expect foreign PE/VC to stay defensive while domestic capital — insurance funds, family offices, domestic AIFs — continues to fill the gap. The pharma and medtech trajectory, meanwhile, is the quiet story worth watching: 62% of a decade's investment in five years points to a structural re-rating, not a cycle.
NationPress
1 May 2026
Frequently Asked Questions
What were India's total PE/VC investments in Q1 2026?
India's PE/VC investments totalled $13.1 billion in Q1 2026, according to a joint EY-IVCA report released on 30 April 2026. This represented a 19% decline year-on-year and a 24% drop from Q4 2025.
Why did PE/VC investment value fall in Q1 2026?
The moderation was driven by heightened geopolitical tensions, persistently high crude oil prices, and sustained rupee depreciation against the dollar, according to EY's Vivek Soni. These factors dampened foreign investor sentiment and triggered intermittent foreign outflows from Indian capital markets.
Which sectors attracted the most PE/VC capital in Q1 2026?
Technology led with $2.2 billion, followed by financial services at $2 billion and real estate at $1.9 billion. Together, these three sectors accounted for 47% of total PE/VC investments in the quarter.
How has the pharma and medical devices sector performed over the past decade?
Since 2016, the pharmaceutical and medical devices sector has attracted $16.4 billion across 303 deals, with 62% of that investment recorded in the last five years alone. The EY-IVCA report describes the sector's PE/VC trajectory as consistently upward over the past decade.
Were deal volumes also down in Q1 2026?
No — deal volumes were nearly flat, with 360 transactions in Q1 2026 compared to 366 in Q1 2025, and up 1% from 358 deals in Q4 2025. The volume resilience contrasts with the sharper decline in deal value.
